Dalibor Sedláček
A5031075527- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV, Drug Use, Sexual Risk
- COVID-19 Clinical Research Studies
- Hepatitis C virus research
- Education, Psychology, and Social Research
- SARS-CoV-2 and COVID-19 Research
- Infectious Encephalopathies and Encephalitis
- HIV/AIDS Impact and Responses
- Long-Term Effects of COVID-19
- Influenza Virus Research Studies
- Cytomegalovirus and herpesvirus research
- COVID-19 and healthcare impacts
- Liver Disease Diagnosis and Treatment
- Mast cells and histamine
- Pregnancy and Medication Impact
- Respiratory viral infections research
- Reproductive System and Pregnancy
- Food Allergy and Anaphylaxis Research
- SARS-CoV-2 detection and testing
- Child and Adolescent Health
- Adolescent Sexual and Reproductive Health
Charles University
2016-2025
University Hospital Plzen
2005-2023
AIDS United
2003
Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure specific antiretroviral drugs CKD.A cohort study including 6843 with at least three serum creatinine measurements corresponding body weight from 2004 onwards.CKD defined as either confirmed (two >or=3 months apart) estimated glomerular filtration rate (eGFR) of 60 ml/min per 1.73 m below for baseline eGFR above 25%...
Antiretrovirals (ARVs) affect bone density and turnover, but their effect on risk of fractures osteonecrosis the femoral head is less understood. We investigated if exposure to ARVs increases both outcomes.EuroSIDA participants were followed assess osteonecrosis. Poisson regression identified clinical, laboratory demographic predictors either outcome. Ever, current, cumulative exposures assessed.During 86118 PYFU among 11820 included persons (median age 41y, 75% male, median baseline CD4...
For people with HIV and CD4+ counts >500 cells/mm3, early initiation of antiretroviral therapy (ART) reduces serious AIDS non-AIDS (SNA) risk compared deferral treatment until are <350 cells/mm3. Whether excess SNA persists once ART is initiated for those who defer uncertain.The Strategic Timing AntiRetroviral Treatment (START) trial, as previously reported, randomly assigned 4684 ART-naive HIV-positive adults .500 cells/mm3 to immediate after random assignment (n = 2325) or deferred (n=...
There is an ongoing debate as to whether SARS-CoV-2 antibodies can be found in patients who have recovered from COVID-19 disease. Currently, there no consensus on the antibodies, if present, are protective. Our regular measurements of starting July 2020, provided us with opportunity becoming acquainted five different immunoassays. A total 149 were enrolled our study. We measured samples using each immunoassay, then performing a virus neutralization test and comparing results this test....
With no expected vaccine for HIV in the near future, we aimed to define current situation and challenges pre- post-exposure prophylaxis (PrEP PEP) Central Eastern Europe (CEE). The Euroguidelines CEE Network Group members were invited respond a 27-item survey including questions on PrEP (response rate 91.6%). was licensed 68.2%; 95 centers offered estimated number around 9000. It available daily (40.1%), on-demand (13.3%), or both forms (33.3%). access <1−80%. Three major barriers lack of...
This retrospective, observational, non-interventional study describes the demographics, characteristics, immunological and virological status, coinfections, healthcare unit of HIV diagnosis follow-up status Ukrainian refugees with newly diagnosed in Czech Republic, a special focus on those late diagnosis. nationals war refugee Republic resident who registered at centres between March 2022 June 2023 new were included. Data collected from medical records. The was State Institute for Drug...
The aim of the study was assessment adherence to antiretroviral (ARV) treatment in a population people living with HIV (PWH), improving awareness PWH, drawing attention risk developing drug resistance and subsequent failure. basic cohort consisted PWH followed up long-term at centre University Hospital Pilsen. Adherence assessed by ARV levels. Nucleoside analogs were determined urine high pressure liquid chromatography (HPLC), relation clinical data, viral load (HIV RNA), absolute CD4 CD8 T...
To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens.NNRTI-naive were included who started treatment with nevirapine (NVP) or efavirenz (EFV) test results available at time of initiation (baseline). Virological failure was defined as two consecutive values > 500 copies/ml after the regimen. Cox models used to investigate (the first values).A total 759 (13%...
Background/objectives: Inadequate HIV care for hard-to-reach populations may result in failing the UNAIDS 90–90–90 goal. Therefore, we aimed to review continuum of and each step Central, Eastern South Europe.Methods: Euro-guidelines Central Europe (ECEE) Network Group were created February 2016. The aim network was standards countries region. Information about stage collected through on-line surveys. Respondents ECEE members chosen based on their expertise involvement national care. Data...
Randomized trials have shown increased risk of suicidality associated with efavirenz (EFV). The START (Strategic Timing Antiretroviral Treatment) trial randomized treatment-naive human immunodeficiency virus (HIV)–positive adults high CD4 cell counts to immediate vs deferred antiretroviral therapy (ART). initial ART regimen was selected prior randomization (prespecified). We compared the incidence suicidal and self-injurious behaviours (suicidal behavior) between groups using proportional...
Low CD4 recovery among HIV-positive individuals who achieve virologic suppression is common but has not been studied initiating treatment at counts of >500 cells/mm.United States, Africa, Asia, Europe and Israel, Australia, Latin America.Among participants randomized to immediate antiretroviral therapy (ART) in the Strategic Timing AntiRetroviral Therapy trial, low was defined as a increase <50 cells/mm from baseline after 8 months despite viral load ≤200 copies/mL. Risk factors for were...
Over 480 000 Ukrainian refugees have arrived in the Czech Republic since Russian invasion of Ukraine 2022, including over 500 people with HIV. This study describes demographics, characteristics, and management HIV Republic.Retrospective, observational, noninterventional study.Ukrainian nationals registering at centers war refugee status were included. Data collected from medical records between 1 March 31 July 2022. The was registered State Institute for Drug Control, ID number...
Objectives The durability of combination antiretroviral therapy (cART) regimens can be measured as time to discontinuation because toxicity or treatment failure, development clinical disease serious long-term adverse events. aim this analysis was compare the nevirapine, efavirenz and lopinavir based on these measures. Methods Patients starting a lopinavir-based cART regimen for first after 1 January 2000 were included in analysis. Follow-up started ≥3 months initiation if viral load <500...
Background Liver damage associated with hepatitis C (HCV) may influence the likelihood of experiencing discontinuation due to toxicities or patient/physician choice (TOXPC) in patients taking combination antiretroviral therapy (cART). Little information address this concern is available from clinical trials as HCV are often excluded. Aims To compare incidence rates TOXPC specific antiretrovial drugs without HCV. Patients/methods A total 4929 EuroSIDA under follow-up January 1999 on a...
Dupilumab is a monoclonal antibody against interleukin 4 (IL-4) receptor α that blocks signaling from IL-4 and IL-13, essential mediators of T helper 2 (Th2) pathway. To date, all clinical trials investigating the use dupilumab excluded patients with human immunodeficiency virus. Herein, we describe safe successful in patient atopic dermatitis, severe therapy resistant asthma, HIV infection.
Estimating the prevalence of accumulated HIV drug resistance in patients receiving antiretroviral therapy (ART) is difficult due to lack testing at all occasions virological failure and with undetectable viral load. A method estimate this for 6498 EuroSIDA who were under follow-up on ART 1 July 2008 was therefore developed by imputing data no prior test results, based probability detecting tested similar profiles.Using results available, predicted intermediate/high-level specific classes...
We assessed differences in antiretroviral treatment (ART) coverage and virological suppression across three HIV key populations, as defined by self-reported transmission category: sex between men, injection drug use (IDU) heterosexual transmission.A multinational cohort study.Within the EuroSIDA study, we region-specific percentages of ART-coverage among those care (<500 copies/ml) on ART, analysed categories using logistic regression.Among 12 872 participants followed from 1 July 2014 to 30...
Objectives The long‐term side effects of stavudine (d4 T ) led to recommendations in 2009 phase out use this drug. We aimed describe temporal patterns d4T across Europe. Methods Patients taking combination antiretroviral therapy ( cART EuroSIDA with follow‐up after 1 J anuary 2006 were included the study. was defined as ‐containing [ plus at least two other antiretrovirals ARVs from any class] or non‐ (at three class, excluding ). Poisson regression used changes prevalence and factors...
The ECEE Network Group investigated early provision of HIV care to war refugees migrating from Ukraine in Central and Eastern Europe (CEE) through an online survey. Fourteen countries admitting on March 31, 2022, completed the Most centers (86%) organized same day antiretroviral therapy (ART) for at least 30 days (77%), but indicated that it may affect local care. CEE put effective emergency mechanisms, which need continuation with international support.
Abstract Background Although people with HIV might be at risk of severe outcomes from infection acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; 2019 [COVID‐19]), regional and temporal differences in SARS‐CoV‐2 testing across Europe have not been previously described. Methods We described the proportions testing, positive test results, hospitalizations due to COVID‐19 between 1 January 2020 31 December 2021 EuroSIDA cohort factors associated being tested for ever positive. Results Of...
Objectives Pre‐exposure prophylaxis (PrEP) for HIV infection is an important intervention control of the epidemic. The incidence increasing in countries Central and Eastern Europe (CEE). Therefore, we investigated change PrEP use CEE over time. Methods Euroguidelines (ECEE) Network Group was initiated February 2016 to compare standards care viral hepatitis infections CEE. Data on access were collected from 23 through online surveys May–June 2017 (76 respondents) November 2018–May 2019 (28...
The extent to which controlled and uncontrolled HIV interact with ageing, European region of care calendar year follow-up is largely unknown.EuroSIDA participants were followed after 1 January 2001 grouped according current progression risk; high risk (CD4 cell count ≤350/μl, viral load ≥10 000 copies/ml), low ≥500 cells/μl, <50 copies/ml) intermediate (other combinations). Poisson regression investigated interactions between risk, age, incidence AIDS or non-AIDS events.A total 16 839...
Abstract Background To date there remains much ambiguity in the literature regarding immunological interplay between SARS‐CoV‐2 and HIV true risk posed to coinfected individuals. There has been little conclusive data use of CD4 cell count viral load stratification as predictors COVID‐19 severity this cohort. Methods We performed a retrospective, observational cohort study on people living with (PLWH) who contracted central eastern Europe. enrolled 536 patients from 16 countries using an...